Toth Financial Advisory Corp Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Toth Financial Advisory Corp raised its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 25.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 91,496 shares of the biopharmaceutical company's stock after acquiring an additional 18,478 shares during the quarter. Toth Financial Advisory Corp's holdings in Bristol-Myers Squibb were worth $5,580,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in BMY. Wealthspire Advisors LLC lifted its position in shares of Bristol-Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after purchasing an additional 170 shares during the period. Edmp Inc. increased its holdings in Bristol-Myers Squibb by 0.4% during the fourth quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company's stock valued at $2,353,000 after buying an additional 171 shares during the period. Bedel Financial Consulting Inc. increased its holdings in Bristol-Myers Squibb by 3.2% during the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock valued at $340,000 after buying an additional 175 shares during the period. King Wealth Management Group increased its holdings in Bristol-Myers Squibb by 2.6% during the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock valued at $413,000 after buying an additional 182 shares during the period. Finally, Signet Investment Advisory Group Inc. increased its holdings in Bristol-Myers Squibb by 2.3% during the fourth quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company's stock valued at $467,000 after buying an additional 189 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Stock Performance

BMY traded up $0.16 during trading on Wednesday, reaching $50.13. 10,973,765 shares of the company's stock were exchanged, compared to its average volume of 13,029,986. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The stock has a market capitalization of $102.01 billion, a P/E ratio of -11.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38. The company's fifty day simple moving average is $48.87 and its 200-day simple moving average is $54.88.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Bristol-Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the firm posted ($4.40) EPS. As a group, research analysts predict that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

BMY has been the topic of several research reports. Wall Street Zen lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. UBS Group lowered their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Piper Sandler began coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $58.00.

Insider Activity

In other news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.